Advantages of intranasal vaccination against SARS-CoV-2
There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science. (Source: World Pharma News)
Source: World Pharma News - July 26, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve™ (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. (Source: World Pharma News)
Source: World Pharma News - July 23, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Antibiotics may help to treat melanoma
Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine. (Source: World Pharma News)
Source: World Pharma News - July 22, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as "Biovac," a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. (Source: World Pharma News)
Source: World Pharma News - July 21, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
Vaccine hesitancy continues to be a hurdle in the development of widespread immunity within the U.S. population as the COVID-19 pandemic enters its second year. Researchers at the University of Cincinnati College of Medicine have developed a computerized decision analytic model to compare projected outcomes of three vaccine strategies: (Source: World Pharma News)
Source: World Pharma News - July 20, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
11 - 22 October, 2021, Virtual Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare as a response to the COVID-19 pandemic, by joining the speaker faculty at Reuters Events Pharma Europe 2021. (Source: World Pharma News)
Source: World Pharma News - July 20, 2021 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Study shows why second dose of COVID-19 vaccine shouldn't be skipped
The second dose of a COVID-19 vaccine induces a powerful boost to a part of the immune system that provides broad antiviral protection, according to a study led by investigators at the Stanford University School of Medicine. The finding strongly supports the view that the second shot should not be skipped. (Source: World Pharma News)
Source: World Pharma News - July 19, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

U.S. FDA grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022. (Source: World Pharma News)
Source: World Pharma News - July 16, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Collaboration between AbbVie, Biogen and Pfizer creates world's largest browsable resource linking rare protein-coding genetic variants to human health and disease
The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. (Source: World Pharma News)
Source: World Pharma News - July 15, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Are silver nanoparticles a silver bullet against microbes?
Antimicrobials are used to kill or slow the growth of bacteria, viruses and other microorganisms. They can be in the form of antibiotics, used to treat bodily infections, or as an additive or coating on commercial products used to keep germs at bay. These life-saving tools are essential to preventing and treating infections in humans, animals and plants, but they also pose a global threat to public health when microorganisms develop resistance to them, a concept known as antimicrobial resistance. (Source: World Pharma News)
Source: World Pharma News - July 14, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

One shot of the Sputnik V vaccine triggers strong antibody responses
A single dose of the Sputnik V vaccine may elicit significant antibody responses against SARS-CoV-2, finds a study published July 13 in the journal Cell Reports Medicine. "Due to limited vaccine supply and uneven vaccine distribution in many regions of the world, health authorities urgently need data on the immune response to vaccines to optimize vaccination strategies," says senior author Andrea Gamarnik of the Fundación Instituto Leloir-CONICET in Buenos Aires, Argentina. (Source: World Pharma News)
Source: World Pharma News - July 13, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

"Long COVID": More than a quarter of COVID-19 patients still symptomatic after 6 months
In a new study of adults from the general population who were infected with COVID-19 in 2020, more than a quarter report not having fully recovered after six to eight months. Those findings are described this week in the open-access journal PLOS ONE by Milo Puhan and colleagues at the University of Zurich, Switzerland. (Source: World Pharma News)
Source: World Pharma News - July 13, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Artificial intelligence could be new blueprint for precision drug discovery
Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. (Source: World Pharma News)
Source: World Pharma News - July 12, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Anti-tumor agent from the intestine
It is believed to be involved in the development of chronic inflammatory intestinal diseases, to trigger diabetes, to be responsible for obesity, even neurological diseases such as multiple sclerosis and Parkinson's could have their causes here - not to mention depressions and autistic disorders. We are talking about the microbiome - the vast collection of bacteria in the human gut. It is estimated that each person carries around 100 trillion bacterial cells in their digestive tract, belonging to several thousand species. (Source: World Pharma News)
Source: World Pharma News - July 9, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Tezepelumab granted Priority Review by U.S. FDA
Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Tezepelumab is being developed by Amgen in collaboration with AstraZeneca. (Source: World Pharma News)
Source: World Pharma News - July 8, 2021 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response
Johnson & Johnson (NYSE: JNJ) (the Company) announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date. (Source: World Pharma News)
Source: World Pharma News - July 7, 2021 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

mRNA vaccines slash risk of COVID-19 infection by 91% in fully vaccinated people
People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. For those few vaccinated people who do still get an infection, or "breakthrough" cases, the study suggests that vaccines reduce the severity of COVID-19 symptoms and shorten its duration. (Source: World Pharma News)
Source: World Pharma News - July 6, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Cancer cells eat themselves to survive
It is the membrane of cancer cells that is at the focus of the new research now showing a completely new way in which cancer cells can repair the damage that can otherwise kill them. In both normal cells and cancer cells, the cell membrane acts as the skin of the cells. And damage to the membrane can be life threatening. The interior of cells is fluid, and if a hole is made in the membrane, the cell simply floats out and dies - a bit like a hole in a water balloon. (Source: World Pharma News)
Source: World Pharma News - July 5, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Researchers find potential path to a broadly protective COVID-19 vaccine using T cells
Gaurav Gaiha, MD, DPhil, a member of the Ragon Institute of MGH, MIT and Harvard, studies HIV, one of the fastest-mutating viruses known to humankind. But HIV's ability to mutate isn't unique among RNA viruses - most viruses develop mutations, or changes in their genetic code, over time. If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. (Source: World Pharma News)
Source: World Pharma News - July 5, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK and Alector announce global collaboration in immuno-neurology
GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. (Source: World Pharma News)
Source: World Pharma News - July 2, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Mefloquine: A promising drug 'soldier' in the battle against COVID-19
Early 2020 saw the world break into what has been described as a "war-like situation": a pandemic, caused by the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the likes of which majority of the living generations across most of the planet have not ever seen. This pandemic has downed economies and resulted in hundreds of thousands of deaths. (Source: World Pharma News)
Source: World Pharma News - July 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants
Researchers at La Jolla Institute for Immunology (LJI) have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants. Their new study, published online on July 1, 2021 in Cell Reports Medicine, shows that both CD4+ "helper" T cells and CD8+ "killer" T cells can still recognize mutated forms of the virus. (Source: World Pharma News)
Source: World Pharma News - July 1, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

COVID-19 vaccine reduces severity, length, viral load for those who still get infected
Individuals who contract COVID-19 even after vaccination are likely to have a lower viral load, experience a shorter infection time and have milder symptoms than people who are unvaccinated, according to research that includes data from ongoing University of Arizona Health Sciences studies. (Source: World Pharma News)
Source: World Pharma News - June 30, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Moderna announces emergency use authorization for its COVID-19 vaccine granted by government of India
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the government of India has issued a registration certificate and a permission to import the COVID-19 Vaccine Moderna for restricted use in an emergency situation. (Source: World Pharma News)
Source: World Pharma News - June 29, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Sanofi launches dedicated vaccines mRNA Center of Excellence
Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy l’Etoile, Lyon (France). (Source: World Pharma News)
Source: World Pharma News - June 29, 2021 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

COVID-19 vaccines have prevented 7.2 million infections and 27,000 deaths in England alone
Latest modelling analysis from Public Health England (PHE) and the University of Cambridge’s MRC Biostatistics Unit suggests that the coronavirus (COVID-19) vaccination programme has so far prevented an estimated 7.2 million infections and 27,000 deaths in England alone. (Source: World Pharma News)
Source: World Pharma News - June 28, 2021 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Roche's Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). (Source: World Pharma News)
Source: World Pharma News - June 25, 2021 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Virus that causes COVID-19 can find alternate route to infect cells
Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2. (Source: World Pharma News)
Source: World Pharma News - June 24, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines. (Source: World Pharma News)
Source: World Pharma News - June 23, 2021 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Drug doubles down on bone cancer, metastasis
Bone cancer is hard to treat and prone to metastasis. Research teams at Rice University and Baylor College of Medicine have a new strategy to attack it. Chemist Han Xiao at Rice and biologist Xiang Zhang at Baylor and their labs have developed an antibody conjugate called BonTarg that delivers drugs to bone tumors and inhibits metastasis. (Source: World Pharma News)
Source: World Pharma News - June 23, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA approves first oral blood thinning medication for children
The U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. (Source: World Pharma News)
Source: World Pharma News - June 22, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

BioNTech announces first patient dosed in Phase 2 clinical trial of mRNA-based BNT111 in patients with advanced melanoma
BioNTech SE (NASDAQ: BNTX, "BioNTech" or "the Company"), announced that the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899). The study is evaluating the Company's therapeutic cancer vaccine candidate BNT111 in combination with Libtayo® (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. (Source: World Pharma News)
Source: World Pharma News - June 22, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced final, confirmatory results from the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalisation or death among high-risk adult outpatients with mild-to-moderate COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 21, 2021 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

COVID-19 dual-antibody therapies effective against variants in animal study
COVID-19 therapies made from antibodies often are given to patients who are at high risk of severe illness and hospitalization. However, there have been nagging questions about whether such antibody therapies retain their effectiveness as worrisome new virus variants arise. (Source: World Pharma News)
Source: World Pharma News - June 21, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AstraZeneca welcomes Court ruling on supply of its COVID-19 vaccine to Europe
AstraZeneca today welcomed the ruling by the Court of First Instance in Brussels. The European Commission had requested 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. The judge ordered delivery of 80.2 million doses by 27 September 2021. (Source: World Pharma News)
Source: World Pharma News - June 18, 2021 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

COVID-19 vaccines pre-prepared in syringes can be safely transported
One of the main reasons for the hold-ups in the mass vaccination campaigns against COVID-19 are the precautions that must be taken regarding the handling of the vaccines and their administration. They have to be transported under very specific conditions and the syringes used for their administration must be prepared at the same vaccination site. (Source: World Pharma News)
Source: World Pharma News - June 17, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac's first-generation COVID-19 vaccine candidate, CVnCoV. (Source: World Pharma News)
Source: World Pharma News - June 17, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

U.S. government purchases additional 200 million doses of Moderna's COVID-19 vaccine
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. government has purchased an additional 200 million doses of Moderna's COVID-19 vaccine, including the option to purchase other COVID-19 vaccine candidates from Moderna's pipeline. (Source: World Pharma News)
Source: World Pharma News - June 16, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

Cancer cells fight for their footing by using an ageing gene
Researchers at the University of Helsinki and the Beatson Institute for Cancer Research in Glasgow have discovered how mutated cells promote their chances to form cancer. Typically, the accumulation of harmful cells is prevented by active competition between multiple stem cells in intestinal glands, called crypts. (Source: World Pharma News)
Source: World Pharma News - June 15, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Study identifies how COVID-19 linked to Alzheimer's disease-like cognitive impairment
A new Cleveland Clinic-led study has identified mechanisms by which COVID-19 can lead to Alzheimer's disease-like dementia. The findings, published in Alzheimer's Research & Therapy, indicate an overlap between COVID-19 and brain changes common in Alzheimer's, and may help inform risk management and therapeutic strategies for COVID-19-associated cognitive impairment. (Source: World Pharma News)
Source: World Pharma News - June 14, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial
Novavax, Inc. (Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. (Source: World Pharma News)
Source: World Pharma News - June 14, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

An omega-3 that's poison for tumors
So-called "good fatty acids" are essential for human health and much sought after by those who try to eat healthily. Among the Omega-3 fatty acids, DHA or docosahexaenoic acid is crucial to brain function, vision and the regulation of inflammatory phenomena. In addition to these virtues, DHA is also associated with a reduction in the incidence of cancer. (Source: World Pharma News)
Source: World Pharma News - June 11, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Common diabetes drug shows promise as treatment for COVID-19 lung inflammation
Metformin is a widely prescribed blood sugar-lowering drug. It is often used as an early therapy (in combination with diet and lifestyle changes) for type 2 diabetes, which afflicts more than 34 million Americans. Metformin works by lowering glucose production in the liver, reducing blood sugar levels that, in turn, improve the body's response to insulin. (Source: World Pharma News)
Source: World Pharma News - June 10, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech to provide 500 million doses of COVID-19 vaccine to U.S. government for donation to poorest nations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies' COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. (Source: World Pharma News)
Source: World Pharma News - June 10, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

FDA grants accelerated approval for Alzheimer's drug
The U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer's, a debilitating disease affecting 6.2 million Americans. Aduhelm was approved using the accelerated approval pathway, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments. (Source: World Pharma News)
Source: World Pharma News - June 9, 2021 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. (Source: World Pharma News)
Source: World Pharma News - June 9, 2021 Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news

CDC COVID-19 study shows mRNA vaccines reduce risk of infection by 91 percent for fully vaccinated people
A new CDC study finds the mRNA COVID-19 vaccines authorized by the Food and Drug Administration (Pfizer-BioNTech and Moderna) reduce the risk of infection by 91 percent for fully vaccinated people. This adds to the growing body of real-world evidence of their effectiveness. Importantly, this study also is among the first to show that mRNA vaccination benefits people who get COVID-19 despite being fully vaccinated (Source: World Pharma News)
Source: World Pharma News - June 8, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson's disease
Bayer AG announced today that BlueRock Therapeutics (BlueRock), a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson's disease patient in their open-label Phase 1 clinical study. (Source: World Pharma News)
Source: World Pharma News - June 8, 2021 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Protein identified as new therapeutic anti-viral target for COVID-19
New research identified a novel interaction between the SARS-CoV-2 spike protein and the galectin-3-binding protein (LGALS3BP) which could be a new therapeutic anti-viral target. The research also found the presence of detectable viral RNA in blood in COVID-19 patients is a strong predictor of mortality. (Source: World Pharma News)
Source: World Pharma News - June 7, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Monoclonal antibody prevents HIV infection in monkeys, study finds
An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows. The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis, or PrEP, therapy to prevent human infection from the virus that causes AIDS. (Source: World Pharma News)
Source: World Pharma News - June 7, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news